Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors
Open Access
- 12 March 2025
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010945
Abstract
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes. We previously reported the engineering of a trastuzumab-equivalent anti-HER2 IgE antibody and showed early evidence of Fc-mediated cancer cell-targeting effects. In the present study, we evaluated the anti-tumoral functions of two anti-HER2 IgEs, trastuzumab and pertuzumab IgE. Methods: In vitro functionality of the two anti-HER2 antibodies was assessed by HER2 phosphorylation and ligand-independent viability assays, as well as basophil (RBL-SX38) degranulation, antibody-dependent cellular cytotoxicity/antibody-dependent cellular phagocytosis(ADCC/ADCP) assays and primary monocyte stimulation assays. The potential to trigger a hypersensitivity type I reaction was investigated using the basophil activation test (BAT). anti-tumoral efficacy was assessed in two humanized HER2+, trastuzumab-resistant models in vivo. Changes in the tumor microenvironment were assessed by flow cytometry or bulk RNA sequencing. Results: We demonstrate the anti-tumoral and immunostimulatory functions of two anti-HER2 IgEs derived from variable region sequences of the clinically available trastuzumab and pertuzumab IgG1 antibodies. IgE engagement of monocytes via the Fc region induced tumor cell cytotoxicity and a pro-inflammatory shift with upregulation of immune-stimulatory CD40, CD80 and CD86, and downregulation of scavenger CD163, cell surface molecules. This was accompanied by enhanced pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β cytokine production. The absence of basophil activation by anti-HER2 IgEs ex vivo in whole blood points to potentially safe administration in humans. In two trastuzumab-resistant HER2+ tumor xenograft models in immunodeficient mice reconstituted with human immune cells, the trastuzumab-equivalent anti-HER2 IgE restricted tumor growth. Treatment was associated with enriched classical (CD14+CD16–) monocyte and lower alternatively-activated (CD163+CD206+) macrophage infiltration, and higher densities of activated CD4+ (CD127loCD25hi) T cells and favorable effector T cell(Teff) to regulatory T cell (Treg) ratios in tumors. Conclusion: Collectively, anti-HER2 IgE maintains Fab-mediated antitumor activity, induces Fc-mediated effects against HER2-expressing tumor cells, and stimulates remodeling of the immune microenvironment in tumors to promote pro-inflammatory cell phenotypes which could translate to improved outcomes for patients.Keywords
Funding Information
- Cancer Research UK City of London Centre (C7893/A31530)
- Worldwide Cancer Research (24-0087)
- Breast Cancer Now (147; KCL-BCN-Q3)
- Epsilogen Ltd (N/A)
- British Skin Foundation (006/R/22)
- Medical Research Council (MR/N013700/1; MR/V049445/1; MR/R015643/1)
This publication has 46 references indexed in Scilit:
- Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancerComputational and Structural Biotechnology Journal, 2021
- Basophil Activation Test Reduces Oral Food Challenges to Nuts and SesameThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Tumor angiogenesis: causes, consequences, challenges and opportunitiesCellular and Molecular Life Sciences, 2019
- IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural statesEBioMedicine, 2019
- Use of the Basophil Activation Test May Reduce the Need for Drug Provocation in Amoxicillin-Clavulanic AllergyThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyCancer Cell, 2016
- Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cellsCancer Immunology, Immunotherapy, 2011
- Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cellsCancer Letters, 2010
- Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix‐metalloproteinase expressionCytoskeleton, 2010
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008